Belviq Lawsuit 2026: 12,000 Patients, 462 Cancers, and No Global Settlement — Can You Still File?

Belviq (lorcaserin) was withdrawn from the U.S. market in 2020 after a five-year, 12,000-patient clinical trial showed users developed more cancers than placebo patients. As of 2026, there is no federal MDL, no approved global settlement, and litigation has largely wound down — but individual cases continue, and anyone who took Belviq before a cancer diagnosis should understand the deadlines that may still apply.

  • The clinical trial behind the withdrawal enrolled about 12,000 patients over five years; 462 in the lorcaserin group developed cancer versus 423 on placebo.
  • The FDA requested Eisai's voluntary withdrawal of Belviq and Belviq XR on February 13, 2020.
  • The Judicial Panel on Multidistrict Litigation declined to create a federal MDL for Belviq cases in 2021.
  • Many cases have been stayed since 2022 while parties pursued settlement talks; no court-approved global settlement exists, though some individual settlements have been reported as confidential.
  • The cancers most frequently cited in the FDA's review were pancreatic, colorectal, and lung cancer.

The Five-Year Trial That Ended Belviq

Belviq, generically lorcaserin — a prescription medicine that acts on serotonin receptors in the brain to promote feelings of fullness — was approved by the FDA in 2012 as an aid to weight loss alongside diet and exercise. Eisai Inc. marketed it in two forms: standard Belviq, taken as a 10 mg tablet twice daily, and Belviq XR, an extended-release version taken once daily.

At the FDA's request, Eisai ran a long-term cardiovascular outcomes trial of about 12,000 men and women at elevated cardiovascular risk. The trial was designed to last five years and to compare patients taking lorcaserin with patients taking a placebo. When the FDA reviewed the final results, the agency concluded the drug's risks outweighed its benefits: 462 patients in the lorcaserin group had developed cancer, compared with 423 in the placebo group. The imbalance appeared across several cancer types, with pancreatic, colorectal, and lung cancers standing out.

On February 13, 2020, the FDA asked Eisai to voluntarily pull Belviq and Belviq XR from the market, urged patients to stop taking it immediately, and advised them to speak with their doctors about alternative weight-loss approaches. Eisai complied. Belviq is no longer sold in the United States, and the FDA also classified it as Pregnancy Category X, meaning evidence of fetal risk exists.

Why the Lawsuits Never Became an MDL

In mass litigation, a multidistrict litigation — abbreviated MDL, a procedure in which similar federal lawsuits are transferred to one judge for coordinated pretrial proceedings — is the standard way drug-injury cases move forward. Belviq cases went a different way: in 2021, the Judicial Panel on Multidistrict Litigation declined to consolidate them, so claims proceeded as individual cases scattered across state and federal courts.

That matters for anyone weighing a claim. Without an MDL, there are no bellwether trials whose verdicts signal settlement values, and no coordinated discovery pushing the litigation toward a single resolution. Each case rises or falls on its own facts: the patient's medical history, the duration of Belviq use, the type and stage of the cancer, and the evidence connecting one to the other. It also means outcomes and timelines are harder to predict from the outside.

For a plain-English walkthrough of how drug-injury litigation actually moves through the courts, the Problem Solved YouTube channel breaks these processes down step by step.

The Settlement Talks: What Is Actually on the Table

In 2022, litigation proceedings in many Belviq cases were stayed — paused by agreement — so that Eisai and plaintiffs' lawyers could focus on negotiating a potential global resolution. As of early 2026, that stay has largely remained in effect, and there has been no announcement of a court-approved, large-scale settlement.

What has happened, quietly, is this: reports from the mass-tort bar indicate that Eisai has been negotiating confidentially and that some individual cases have reached private settlements. These confidential resolutions are not published, carry no admission, and set no precedent for other cases. They do, however, tell a careful reader something meaningful: the manufacturer is engaging, case by case, even as the litigation as a whole shows little public movement.

It would be a mistake to read quiet as finished. Stayed proceedings are not dismissed proceedings. But it would be an equal mistake to assume a resolution is imminent — years have now passed with no global deal, and the litigation has, by every informed account, substantially wound down.

The Quiet Crisis: Statutes of Limitations

The most urgent issue in Belviq litigation is not settlement values. It is time. Every state imposes a statute of limitations — a legal deadline after which a claim can be permanently barred — on product-liability and personal-injury cases, and the clock typically starts running when a person discovers, or should have discovered, the connection between the drug and the injury.

Belviq was withdrawn more than six years ago. For someone diagnosed with cancer in 2020 or 2021 who knew they had taken the drug, the deadline in many states may already have passed. Some states toll — pause — the clock for circumstances like minority or delayed discovery, and the exact trigger varies enormously from state to state, but the margin for delay has narrowed dramatically.

If you took Belviq and were later diagnosed with cancer, the single most important step is to have an attorney experienced in pharmaceutical litigation evaluate your timeline immediately. State-by-state deadlines for injury claims in 2026 show how unforgiving these clocks can be — and how much they differ between jurisdictions.

Who Might Still Have a Claim

Generally, adults who took Belviq or Belviq XR for weight loss and were later diagnosed with cancer — particularly pancreatic, colorectal, or lung cancer — or the families of those who died, may have had a claim depending on pharmacy records, dates of use, and pathology. The same tension between regulatory action and individual claims recurs in cases involving Zantac and Ozempic, where understanding the pattern helps you ask a lawyer the right questions.

What to Do Right Now

First, do not assume the litigation's quiet ending means you are out of options — and do not assume, either, that time remains. Keep your pharmacy records, pill bottles, and oncology reports; courts and settlement administrators treat contemporaneous documentation as far more persuasive than memory.

Second, be skeptical of any advertisement quoting specific settlement amounts for Belviq cases. There is no approved global settlement and no official payment schedule, so any number presented as a likely recovery is, at best, an estimate drawn from other litigations. Compensation depends entirely on individual circumstances, and most settlements in pharmaceutical cases are confidential.

This article provides general information only and is not legal or medical advice. Belviq litigation involves state-specific deadlines and individual facts; consult a qualified attorney about your situation and a medical professional about your health.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

People who took Belviq or Belviq XR and were later diagnosed with cancer, especially pancreatic, colorectal, or lung cancer. How: those cancers were the types most prominent in the FDA review of the five-year, 12,000-patient trial, in which 462 patients in the lorcaserin group developed cancer versus 423 on placebo.

People who only recently connected a cancer diagnosis to Belviq use. How: statutes of limitations are the critical barrier in this article, and an experienced pharmaceutical-litigation attorney can evaluate the specific timeline immediately, including any discovery-rule argument.

People who can document both the prescription and the diagnosis. How: there is no certified class action and no federal MDL, so any claim is an individual case evaluated on its own facts, starting with those records.

Who does not benefit:

Anyone expecting to join a Belviq class action or a global settlement program. How: there is no certified Belviq class action, the Judicial Panel declined a federal MDL in 2021, and no court-approved global settlement exists.

Anyone who took Belviq with no cancer diagnosis or other documented injury. How: the claims described in this article centre on the cancer findings in the trial, not on taking the drug alone.

Anyone assuming the filing deadline is still open regardless of timing. How: the drug was withdrawn on February 13, 2020, and in many states the deadline for claims may already have passed depending on when the injury was discovered.

Another prescription-drug litigation that also proceeds case by case, rather than through a single class payout, is covered in our guide to the Ozempic lawsuits.

Is there a Belviq class action lawsuit I can join in 2026?

No. There is no certified Belviq class action and no federal MDL. Cases have proceeded individually in state and federal courts, many of them stayed since 2022 while settlement talks continued. Any claim would be an individual case evaluated on its own facts.

Has there been a Belviq settlement?

There has been no court-approved global settlement as of 2026. Reports from the mass-tort bar indicate some individual cases reached confidential settlements through negotiations with Eisai, but no official settlement program or payment schedule has been announced.

Can I still file a Belviq lawsuit in 2026?

Possibly, but statutes of limitations are the critical barrier. The drug was withdrawn in February 2020, so in many states the deadline for claims may already have passed depending on when the injury was discovered. An experienced pharmaceutical-litigation attorney can evaluate your specific timeline immediately.

What cancers were linked to Belviq?

The FDA's review of the five-year, 12,000-patient trial highlighted pancreatic, colorectal, and lung cancers as the types most prominent among Belviq users. A range of other cancer types was also reported in the trial data.

Who benefits most from a Belviq claim evaluation?

People who took Belviq or Belviq XR and were later diagnosed with cancer benefit most, especially pancreatic, colorectal, or lung cancer, the types most prominent in the FDA review of the five-year, 12,000-patient trial, in which 462 patients in the lorcaserin group developed cancer versus 423 on placebo. Because there is no class action or MDL, each case is evaluated individually on its own prescription and diagnosis records.

Who does not benefit, and how do I start a Belviq evaluation?

People expecting a class-action claim form or a global settlement payout do not benefit, because no certified class action and no court-approved global settlement exists. Start by gathering prescription records for Belviq or Belviq XR, the cancer diagnosis records, and a timeline of use and diagnosis, and have a pharmaceutical-litigation attorney evaluate the deadline immediately, since the drug was withdrawn on February 13, 2020.

Watch on YouTube

Problem Solved on YouTube